Caisse DE Depot ET Placement DU Quebec lifted its stake in Amgen (NASDAQ:AMGN) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 422,233 shares of the medical research company’s stock after acquiring an additional 70,730 shares during the period. Caisse DE Depot ET Placement DU Quebec owned 0.06% of Amgen worth $73,426,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. increased its position in Amgen by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after buying an additional 489,720 shares in the last quarter. Bank of New York Mellon Corp increased its position in Amgen by 1.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after buying an additional 140,117 shares in the last quarter. Geode Capital Management LLC increased its position in Amgen by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 8,110,133 shares of the medical research company’s stock valued at $1,407,552,000 after buying an additional 199,838 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares in the last quarter. 79.54% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 4,575 shares of company stock worth $818,330 in the last 90 days. Company insiders own 0.19% of the company’s stock.
Shares of AMGN stock opened at $171.38 on Tuesday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $114,595.02, a PE ratio of 13.62, a PEG ratio of 2.10 and a beta of 1.36. Amgen has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the prior year, the company posted $2.89 earnings per share. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. research analysts anticipate that Amgen will post 13.26 EPS for the current year.
Amgen announced that its Board of Directors has approved a share repurchase program on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.08%. Amgen’s payout ratio is 41.97%.
Several brokerages recently issued reports on AMGN. Mizuho upped their target price on Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, February 12th. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Morgan Stanley reduced their target price on Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. TheStreet lowered Amgen from a “b-” rating to a “c+” rating in a research report on Wednesday, April 11th. Finally, BMO Capital Markets upped their target price on Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. Amgen currently has a consensus rating of “Hold” and a consensus price target of $190.57.
TRADEMARK VIOLATION WARNING: “Caisse DE Depot ET Placement DU Quebec Raises Holdings in Amgen (AMGN)” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/04/17/caisse-de-depot-et-placement-du-quebec-raises-holdings-in-amgen-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.